AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer's and erectile dysfunction, all of which have been linked to atherosclerosis. Additional areas of interest are obesity, lipomas and other lipid accumulations. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone.
The comparative mechanisms of action for AHRO-001 demonstrate successful outcomes according to eight measures
On November 6, 2012, AtheroNova received a Notice of Issuance from the USPTO for US Patent 8,304,383 for its patent application for Dissolution of Arterial Plaque. This patent issuance is the first major step in the development of the Company’s intellectual property portfolio involving lipid modulation and reduction.